Charles River Laboratories International, Inc.

Company facts

Industry

Services-Commercial Physical & Biological Research

Headquarters

Wilmington, Massachusetts

Most recent report

8-K, filed Nov 9, 2026

Incorporated

N/A

Filings on record

1,002+ filings

On EDGAR

CIK 1100682

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 4 of 11 sections worth reading, with 1 positive, 16 notable, and 2 negative flags.

• Financial Statements (Item 1)

  Massive tax benefit, divestitures, acquisitions, restructuring, and litigation updates all in one quarter.
  Notable

  • Acquired Cambodian NHP supplier for $507M in Jan 2026, funded by cash and credit; $5M deferred consideration remains.
  • Repurchased 1.7M shares for $300M under a $1B program; $700M remaining as of Sep 2026.
  • Securities class action revived on appeal in Aug 2025; second amended complaint filed Sep 2026, motion to dismiss pending.
  Negative

  • Divested CDMO and Cell Solutions in May 2026, recording a $181.7M pre-tax loss for the nine months ended Sep 2026.

• Management's Discussion (Item 2)

  Major divestitures, a $507M NHP supplier acquisition, a $201M tax benefit, and segment operating income swings.
  Positive

  • Operating income rose 51.4% to $202.6M in Q3 2026, margin up 730 bps to 20.6%, helped by divestitures.
  Notable

  • DSA backlog grew to $2.0B from $1.9B, signaling improved demand from biotech funding.
  • Launched 'Create the Future' restructuring targeting $300M+ annual savings by end of 2026; $73.8M in charges so far.
  • Acquired Cambodian NHP supplier for $507.3M; paid $170M of deferred consideration in 9 months, $5M remains.
  • Revenue fell 2.2% to $982.7M in Q3 2026, driven by divestitures; organic growth was mixed.
  • Net income jumped to $333.1M in Q3 2026 from $54.4M, mainly from a $201M tax benefit.
  • A $201M tax benefit from reversing an unrecognized tax reserve drove a -96% effective tax rate in Q3 2026.

• Legal Proceedings (Item 1)

  Securities class action revived on appeal; derivative suits stayed but active.
  Notable

  • Lead plaintiff replaced due to lack of standing; new lead plaintiff appointed September 2, 2026.
  • Second amended complaint narrows class period to Nov 30, 2022 – Mar 15, 2023, removing non-actionable claims.
  • Company cannot estimate maximum potential loss for any of these matters.
  • Two derivative lawsuits stayed pending resolution of the class action motion to dismiss.
  Negative

  • First Circuit reversed dismissal of securities fraud claims on August 15, 2025, reviving the case.

• Other Information (Item 5)

  CEO terminated two plans and adopted a new one; three insiders set up sales plans in Q3 2026.
  Notable

  • CEO terminated two plans and adopted a new one for up to 24,814 shares, first trade no earlier than Nov 20, 2026.
  • Director Nancy Andrews adopted a plan for up to 2,539 shares, first trade no earlier than Nov 26, 2026.
  • Chief People Officer Victoria Creamer adopted a plan for up to 12,996 shares, first trade no earlier than Nov 27, 2026.

What changed: Sep 2026 vs. Jun 2026

About 5% of CRL's Sep 2026 10-Q is new information. 13 paragraphs were added, 156 changed, and 28 removed. Below are the most important lines SECSift identified.

• Item 2 56
• Item 1 41
• Item 5 5
• Item 4 2
• Item 6 2